Vir’s early T cell engager data offer first look at cancer pivot

Interim data on two T cell engagers that Vir Biotechnology licensed from Sanofi last year have begun to justify the biotech’s strategic shift into oncology. The company's stock {$VIR} climbed 47% in ...